Special Issue

Biofilms in Wounds: New Advances in Therapy and in Healing Management

Message from the Guest Editors

Biofilm is the predominant mode of life for bacteria and yeasts and is presently implicated in numerous human diseases. In fact, the majority of non-healing wounds contain biofilms, contributing to the high global cost of chronic wounds. Non-healing wounds with biofilms have a low-grade and persistent inflammatory response, which leads to impaired epithelialization and granulation tissue formation, and reduced susceptibility to antimicrobial agents. Furthermore, a compromised host defense severely delays the healing of wounds in patients, contributing to infection. Therefore, reducing the biofilm's presence in wounds is, indeed, a critical element of effective wound care. Strategies to manage biofilm and encourage progression to wound healing are urgently needed. We warmly welcome you to join us in this effort. Reviews or original research articles are most welcome. We look forward to receiving your contributions.

Guest Editors

Dr. Célia Fortuna Rodrigues

Dr. Karishma Kaushik

Dr. Caitlin Light

Deadline for manuscript submissions closed (30 September 2020)



Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/20980

Biomedicines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biomedicines@mdpi.com

mdpi.com/journal/ biomedicines





Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

 Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).